Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

WHIPPANY, N.J.--(BUSINESS WIRE)--For the fourth consecutive year, Bayer U.S. has been awarded and recognized by The Disability Equality Index (DEI) as a Best Place to Work for Disability Inclusion. This is the second year that Bayer has received a top score of 100% in the DEI, which is the most comprehensive disability inclusion tool designed and embraced by both business leaders and disability advocates across the country. Since 2019, Bayer's DEI score has improved year-over-year, recognizing

Bayer Earns Top Score on 2022 Disability Equality Index

Jazz Pharmaceuticals

Merck

Merck (MRK), Bayer (BAYRY) and Jazz Pharmaceuticals (JAZZ) are three large drugmakers that are good stocks to buy.

3 Drugmaker Stocks Worth Buying to Boost Your Portfolio Health

Roche Holding AG

BAYRY vs. RHHBY: Which Stock Is the Better Value Option?

BASF SE

Bayer AG and BASF have won a new trial on $60 million in punitive damages they were ordered to pay a Missouri peach farmer who said dicamba, a herbicide they produced, drifted onto his orchard and harmed his crops.

Bayer, BASF win new trial on $60 million damage award in weedkiller lawsuit

Loncar Cancer Immunotherapy ETF

Seagen

Oncology remains the fastest growing pharma segment, where innovation is largely driven by emerging small companies. The global oncology market is estimated at c US$175–180bn and is anticipated to more than double from current levels within the next seven years to address the rising incidence rates.

Oncology ABCs: A Small-Cap Biopharma Prospectus Series

Bayer AG is one of the world's largest “life-science” conglomerates. For a global company with such a strong global presence and portfolio of valuable intellectual property, Bayer stock is trading ridiculously cheap.

Bayer: Risk/Reward Skewed To The Upside

BOSTON--(BUSINESS WIRE)--Bayer AG announced today the opening of its new Research and Innovation Center at Kendall Square in Boston-Cambridge, Massachusetts (U.S.A.), expanding the company's footprint into one of the world's most innovative pharmaceutical research and development locations. Representing a total $140M USD investment into the area, Bayer's 62,100-square-foot facility houses a new center of precision molecular oncology research equipped with state-of-the-art laboratories and offic

Bayer Opens New Research & Innovation Center in Boston-Cambridge Demonstrating Its Commitment to Precision Oncology

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer's KERENDIA® (finerenone) was recognized by the American Diabetes Association (ADA) Standards of Medical Care in Diabetes—2022 with a new grade A recommendation* for improving cardiovascular (CV) outcomes and reducing the risk of chronic kidney disease (CKD) progression in patients with CKD associated with type 2 diabetes (T2D).1 KERENDIA was approved in the United States based on the results of FIDELIO-DKD, to reduce the risk of sustained eGFR decline, end

Bayer's KERENDIA® (finerenone) Receives New Recommendations From American Diabetes Association for Improving Cardiovascular Outcomes and Managing Patients With Chronic Kidney Disease Associated With Type 2 Diabetes

PITTSBURGH--(BUSINESS WIRE)--Bayer today unveiled Calantic™ Digital Solutions, a new cloud-hosted platform delivering access to digital applications, including AI-enabled programs, for medical imaging. The offering contains tools to help triage critical patient findings for expedited review, improve lesion detection and automate tasks. With this launch, Bayer expands its radiology portfolio beyond contrast media, devices, software and services, with the ultimate goal of supporting healthcare pr

Bayer Launches Calantic™ Digital Solutions to help Address Radiology Industry Challenges

(Reuters) -The U.S. Supreme Court on Monday rejected another Bayer AG bid to dismiss litigation alleging that its Roundup weedkiller causes cancer as the German pharmaceutical and chemical giant tries to avoid potentially billions of dollars in damages.

U.S. Supreme Court again nixes Bayer challenge to weedkiller suits

The US Supreme Court has rejected a bid by Bayer AG (ETR:BAYN, OTC:BAYZF) to dismiss lawsuits by customers alleging the company's Roundup weedkiller causes cancer, a move that could cost the chemical group billions in compensation. Supreme Court justices rejected a Bayer appeal and upheld a lower court decision that awarded US$25mln in damages to California resident Edwin Hardeman, a Roundup user who allegedly blamed his cancer on the German company's glyphosate-based weedkillers.

Bayer's attempt to end Roundup lawsuits rejected by US Supreme Court

The justices left in place a $25 million judgment in favor of a California man who says he developed cancer from using Roundup for decades on his San Francisco Bay Area property.

Supreme Court rejects Bayer's bid to stop Roundup weedkiller lawsuits

The Supreme Court has rejected Bayer's appeal to shut down thousands of lawsuits claiming that its Roundup weedkiller causes cancer.

Supreme Court rejects Bayer bid to stop Roundup lawsuits

The U.S. Supreme Court on Tuesday rejected Bayer AG's bid to dismiss legal claims by customers who contend its Roundup weedkiller causes cancer as the German company seeks to avoid potentially billions of dollars in damages.

U.S. Supreme Court rejects Bayer bid to nix Roundup weedkiller suits

A U.S. jury found Bayer's Roundup weedkiller did not cause an Oregon man's cancer, the German agriculture and pharmaceuticals company said on Saturday, handing the firm its fourth consecutive trial victory over such claims.

Bayer wins fourth Roundup weedkiller case in U.S

The U.S. Supreme Court on Monday took no action on Bayer AG's bid to dismiss legal claims by customers who contend its Roundup weedkiller causes cancer as the German company seeks to avoid potentially billions of dollars in damages.

U.S. Supreme Court takes no action on Bayer bid to nix weedkiller suits

The U.S. Supreme Court could announce as soon as Monday whether it will hear Bayer's bid to dismiss claims its Roundup weedkiller causes cancer as the company seeks to avoid potentially billions of dollars more in damages and payouts.

U.S. Supreme Court will soon decide whether to hear Bayer's weedkiller case

LEVERKUSEN, Germany & SAN DIEGO--(BUSINESS WIRE)--Bayer AG and its wholly owned San Diego-based subsidiary Vividion Therapeutics, Inc. (Vividion) will highlight how the two companies have fostered innovation and collaboration through Bayer's “arm's length” operating model during a presentation at the 2022 BIO International Convention. Bayer has built a strong partnership with Vividion since its acquisition of the biopharmaceutical company in 2021, deploying an innovative business model that all

Bayer's Vividion Emerging as Significant Player in San Diego Biotech Hub

Cisco Systems

Equinor

Intel

AT&T

Unilever

Volkswagen AG

These seven blue-chip stocks are trading at relative bargains and they can all be added to your portfolio for less than $250. The post 7 Blue-Chip Stocks to Buy Now if You Have $250 to Spend appeared first on InvestorPlace.

7 Blue-Chip Stocks to Buy Now if You Have $250 to Spend

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, one of the country's leading life-sciences companies, today announced two changes to its U.S. Country Leadership Team. Brian Branca has been appointed to the position of Bayer U.S. Chief Financial Officer (CFO), effective June 1, 2022. Branca has been with Bayer since 2006 and most recently served as Bayer U.S. Vice President and Treasurer. He has held numerous financial leadership roles throughout his tenure with the company, including serving as CFO for

Bayer Appoints Two New Members to U.S. Country Leadership Team

Grifols, S.A.

Takeda Pharmaceutical

These three healthcare stocks should hold their value for years.

Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond

Atara Biotherapeutics Inc (NASDAQ: ATRA) received notification that Bayer AG's (OTC: BAYRY) intends to end the exclusive worldwide licensing agreement for mesothelin-directed CAR T-cell therapies. The collaboration included the funding and development of ATA3271,.

Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present new data across its oncology portfolio at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7, 2022. These presentations continue to reinforce Bayer's position as an innovator in oncology and ongoing dedication to advancing oncology treatments for patients on a global scale. NUBEQA® (darolutamide) data presented will include overall survival (OS) and prostate-specific antigen (PSA) results from the investigationa

Bayer to Present Key Data Across Oncology Portfolio Showcasing Significant Advances in Cancer Care at 2022 ASCO Annual Meeting

Shares in Bayer AG fell in opening trade on Wednesday after a U.S. Justice department brief recommended that the Supreme Court reject a company appeal to review a case linking its Roundup weedkiller to a type of cancer.

Bayer shares plunge after U.S. Justice Department asks Supreme Court to reject Roundup appeal

Bayer Aktiengesellschaft (OTCPK:BAYZF) Q1 2022 Results Conference Call May 10, 2022 8:00 AM ET Company Participants Oliver Maier - Head, IR Werner Baumann - CEO Wolfgang Nickl - CFO Rodrigo Santos - President, the Crop Science Division Stefan Oelrich - Head, the Pharmaceuticals Division Conference Call Participants Vincent Andrews - Morgan Stanley Pete Verdult - Citigroup Sachin Jain - Bank of America Michael Leuchten - UBS James Quigley - Morgan Stanley Keyur Parekh - Goldman Sachs Falko Friedrich - Deutsche Bank Christian Faitz - Kepler Cheuvreux Steve Byrne - Bank of America Richard Vosser - JPMorgan Operator Ladies and gentlemen, thank you for standing by. Welcome to Bayer's Investor and Analyst Conference Call on the First Quarter 2022 Results.

News for Bayer AG Stock (BAYRY)